Newsfeeds Archive - Spark Newswire

5 minute read

‘Oregon’s First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching’ – Marijuana Moment

June 12, 2:07 PM

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be

CMPS

2 minute read

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

By Jelena Martinovic

May 16, 11:25 AM

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB

2 minute read

Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate

By Nina Zdinjak

May 14, 8:00 AM

Psychedelics biotechÂ firm,Â Enveric Biosciences (NASDAQ:ENVB)Â has signed a non-binding term sheet to out-license a class of Novel Psilocin ProdrugsÂ (NPP)Â to Vancouver,…

ENVB

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

May 8, 8:06 AM

Gainers Repare Therapeutics (NASDAQ:RPTX) shares rose 34.1% to $4.4 during Wednesday’s pre-market session. The company’s market cap stands…

CLOV

3 minute read

Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods

By Nina Zdinjak

May 8, 7:05 AM

The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance.

ENVB

2 minute read

“FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month” – Marijuana Moment

By Benzinga Newsdesk

May 7, 11:54 AM

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy

CMPS

3 minute read

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More

By Lara Goldstein

April 17, 8:42 AM

DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings The Drug Enforcement Administration (DEA)…

AGNPF

4 minute read

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Avi Kapoor

April 3, 1:56 PM

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.

ABAT